In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I

International Journal of Neuropsychopharmacology

Volumn 17, Issue 5, 2014, Pages 697-703

  Kim, WooChan ^a   Tateno, Amane ^a   Arakawa, Ryosuke ^a,b   Sakayori, Takeshi ^a   Ikeda, Yumiko ^a   Suzuki, Hidenori ^a   Okubo, Yoshiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Abuse liability; dopamine transporter; modafinil; positron emission tomography

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE; MODAFINIL; N (3 IODOPROP 2E ENYL) 2 BETA CARBOMETHOXY 3 BETA (4 METHYLPHENYL)NORTROPANE F 18; RADIOLIGAND; UNCLASSIFIED DRUG; (E)-N-(3-IODOPROP-2-ENYL)-2BETA-CARBOFLUOROETHOXY-3BETA-(4'-METHYL-PHENYL) NORTROPANE; BENZHYDRYL DERIVATIVE; NORTROPANE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; WAKEFULNESS PROMOTING AGENT;

ADULT; ARTICLE; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; MIDDLE AGED; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEUS ACCUMBENS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BLOOD; BRAIN; BRAIN MAPPING; DIAGNOSTIC USE; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; YOUNG ADULT;

ADULT; BENZHYDRYL COMPOUNDS; BRAIN; BRAIN MAPPING; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; WAKEFULNESS-PROMOTING AGENTS; YOUNG ADULT;

EID: 84897453966     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001612     Document Type: Article

References (51)

1. Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL (2010) Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology (Berl) 210:439-448
2. Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, Suhara T (2010) Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 71:1131-1137
3. Bruggisser M, Bodmer M, Liechti ME (2012) [Methylphenidate misuse]. Praxis (Bern 1994) 101:299-305
4. Chevassus H, Farret A, Gagnol JP, Ponçon CA, Costa F, Roux C, Galtier F, Petit P (2012) Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). Eur J Clin Pharmacol 69:779-787
5. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, Frangin Y, Mauclaire L, Besnard JC, Guilloteau D (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl) nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3', 4'-disubstituted phenyl)nortropane. New high-Affinity and selective compounds for the dopamine transporter. J Med Chem 40:1366-1372
6. Emond P, Guilloteau D, Chalon S (2008) PE2I: A radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci Ther 14:47-64
7. Farde L, Halldin C, Muller L, Suhara T, Karlsson P, Hall H (1994) PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse 16:93-103
8. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR, Hitzemann R, Logan J, Bendriem B, Gatley SJ, Christman D (1989) Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 4:371-377
9. Greenhill LL (2006) The science of stimulant abuse. Pediatr Ann 35:552-556
10. Gurevich EV, Joyce JN (1996) Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology 14:309-323
11. Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L (2003) [(11)C]PE2I: A highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 30:1220-1230
12. Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P, Roivainen A, Någren K, Halldin C, Farde L, Hietala J (2008) Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: Quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 28:1059-1069
13. Innis RB et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539
14. Ito H, Sudo Y, Suhara T, Okubo Y, Halldin C, Farde L (2001) Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D(2) dopamine receptors in the human brain. Neuroimage 13:531-539
15. Jasinski DR, Kovacević-Ristanović R (2000) Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 23:149-156
16. Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L (2006) Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study. Eur J Nucl Med Mol Imaging 33:657-668
17. Kollins SH, MacDonald EK, Rush CR (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: A review. Pharmacol Biochem Behav 68:611-627
18. Kruszewski SP, Klotz SG (2007) Modafinil: Mischaracterization. J Clin Psychiatry 68:970-971; author reply 971-972
19. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Hietala J (1998) [18F]CFT [(18F)WIN 35428], a radioligand to study the dopamine transporter with PET: Characterization in human subjects. Synapse 28:244-250
20. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
21. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54:800-805
22. Lynch G, Palmer LC, Gall CM (2011) The likelihood of cognitive enhancement. Pharmacol Biochem Behav 99:116-129
23. Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ (1998) Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 29:93-104
24. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni E, Spencer TJ, Bonab AA, Miller GM, Fischman AJ (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319:561-569
25. Maher B (2008) Poll results: Look who's doping. Nature 452:674-675
26. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 163:102-105
27. Minzenberg MJ, Carter CS (2008) Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33:1477-1502
28. Myrick H, Malcolm R, Taylor B, LaRowe S (2004) Modafinil: Preclinical, clinical, and post-marketing surveillance-A review of abuse liability issues. Ann Clin Psychiatry 16:101-109
29. Odano I, Varrone A, Savic I, Ciumas C, Karlsson P, Jucaite A, Halldin C, Farde L (2012) Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter-Application to juvenile myoclonic epilepsy. Neuroimage 59:3582-3593
30. PDR Network (2006) Provigil (modafinil). In: Chesanow N, Fleming H (eds) Physicians' desk reference, 60th edn, pp1002-1007. New Jersey: Thompson PDR
31. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to selfadministration of cocaine. Science 237:1219-1223
32. Robertson P Jr., Hellriegel ET (2003) Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42:123-137
33. Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T (2012) Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med 53:1065-1073
34. Schwartz JR, Feldman NT, Bogan RK (2005) Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry Clin Neurosci 17:405-412
35. Seki C, Ito H, Ichimiya T, Arakawa R, Ikoma Y, Shidahara M, Maeda J, Takano A, Takahashi H, Kimura Y, Suzuki K, Kanno I, Suhara T (2010) Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: Evaluation of reference tissue models. Ann Nucl Med 24:249-260
36. Sembower MA, Ertischek MD, Buchholtz C, Dasgupta N, Schnoll SH (2013) Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. J Addict Dis 32:26-38
37. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA, Fischman AJ (2006) PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-And long-Acting oral methylphenidate. Am J Psychiatry 163:387-395
38. Spencer TJ, Madras BK, Bonab AA, Dougherty DD, Clarke A, Mirto T, Martin J, Fischman AJ (2010) A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [11C]altropane and [11C]raclopride. Biol Psychiatry 68:964-970
39. Spencer TJ, Bonab AA, Dougherty DD, Mirto T, Martin J, Clarke A, Fischman AJ (2012) Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: A positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. J Clin Psychiatry 73:346-352
40. Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Mash DC (1995) Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse 21:364-372
41. Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, Nakamura H, Kumita S, Okubo Y (2013) Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, Blonanserin: A PET study with [11C]Raclopride and [11C]FLB 457 in schizophrenia. J Clin Psychopharmacol 33:162-169
42. Varnas K, Halldin C, Hall H (2004) Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22:246-260
43. Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, Gulyas B, Halldin C (2009) In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F] FE-PE2I, a new dopamine transporter PET radioligand. Synapse 63:871-880
44. Varrone A, Tóth M, Steiger C, Takano A, Guilloteau D, Ichise M, Gulyás B, Halldin C (2011) Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med 52:132-139
45. Varrone A, Gulyás B, Takano A, Stabin MG, Jonsson C, Halldin C (2012) Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: Prediction for human studies. Nucl Med Biol 39:295-303
46. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331
47. Volkow ND, Wang GJ, Fowler JS, Learned-Coughlin S, Yang J, Logan J, Schlyer D, Gatley JS, Wong C, Zhu W, Pappas N, Schueller M, Jayne M, Carter P, Warner D, Ding YS, Shea C, Xu Y (2005) The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry 57:640-646
48. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F (2009a) Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (Suppl. 1):3-8
49. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, Wang GJ, Jayne M, Hooker JM, Wong C, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog-Torres K (2009b) Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA 301:1148-1154
50. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, Chan B, Folio T, Scheffel U, Ricaurte GA, Neumeyer JL, Wagner HN Jr., Kuhar MJ (1993) In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35428. Synapse 15:130-142
51. Wong YN, King SP, Simcoe D, Gorman S, Laughton W, McCormick GC, Grebow P (1999) Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects. J Clin Pharmacol 39:281-288